Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer
- 1 January 2002
- Vol. 59 (1) , 73-78
- https://doi.org/10.1016/s0090-4295(01)01440-6
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Long-Term Efficacy and Safety of Nilutamide Plus Castration in Advanced Prostate Cancer, and the Significance of Early Prostate Specific Antigen NormalizationJournal of Urology, 1997
- Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the european organization for research and treatment of cancer–-genitourinary group study 30853Cancer, 1993
- Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer.Journal of Clinical Oncology, 1993
- Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancerCancer, 1992
- The Clinical Usefulness of Serum Prostate Specific Antigen After Hormonal Therapy of Metastatic Prostate CancerJournal of Urology, 1992
- Prostate specific antigen in diagnosis, staging, and follow-up of prostate cancerThe Prostate, 1992
- Prognostic Significance of Prostate Specific Antigen in Endocrine Treatment for Prostatic CancerJournal of Urology, 1990
- Prostatic Specific Antigen and the Prediction of Prognosis in Metastatic Prostatic CancerCancer, 1990
- Clinical use of Prostate Specific Antigen in Patients with Prostate CancerJournal of Urology, 1989
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958